VYNE Therapeutics (VYNE) shares were edging higher Monday morning after the biopharmaceutical company reported "positive" phase 1a results for its novel BD2-selective BET inhibitor VYN202.
The company said the results support the inhibitor's potential as a new oral treatment for various immune-mediated disorders.
VYN202 showed a favorable safety and tolerability profile without any drug-related adverse events in the phase 1a trial as well as "robust pharmacodynamic activity," VYNE said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。